Viridian Therapeutics Inc [VRDN] stock is trading at $32.85, down -0.54%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The VRDN shares have gain 3.30% over the last week, with a monthly amount glided 14.18%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Viridian Therapeutics Inc [NASDAQ: VRDN] stock has seen the most recent analyst activity on December 10, 2025, when Wedbush reiterated its Outperform rating and also boosted its price target to $47 from $42. On November 24, 2025, Truist initiated with a Buy rating. Wells Fargo downgraded its rating to a Equal Weight and reduced its price target to $27 on December 19, 2024. In a note dated September 11, 2024, Needham reiterated a Buy rating on this stock and boosted its target price from $30 to $38.
Viridian Therapeutics Inc [VRDN] stock has fluctuated between $9.90 and $34.04 over the past year. Currently, Wall Street analysts expect the stock to reach $41.57 within the next 12 months. Viridian Therapeutics Inc [NASDAQ: VRDN] shares were valued at $32.85 at the most recent close of the market. An investor can expect a potential return of 26.54% based on the average VRDN price forecast.
Analyzing the VRDN fundamentals
Viridian Therapeutics Inc [NASDAQ:VRDN] reported sales of 70.79M for the trailing twelve months, which represents a growth of 81958.14%. Gross Profit Margin for this corporation currently stands at 0.6% with Operating Profit Margin at -1218.31%, Pretax Profit Margin comes in at -1128.07%, and Net Profit Margin reading is -1128.07%. To continue investigating profitability, this company’s Return on Assets is posted at -0.59, Equity is -0.55 and Total Capital is -0.7. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 32.25 points at the first support level, and at 31.65 for the second support level. However, for the 1st resistance point, the stock is sitting at 33.47, and for the 2nd resistance point, it is at 34.09.
Ratios To Look Out For
For context, Viridian Therapeutics Inc’s Current Ratio is 11.28. As well, the Quick Ratio is 11.28, while the Cash Ratio is 2.23. Considering the valuation of this stock, the price to sales ratio is 44.29, the price to book ratio is 8.60.
Transactions by insiders
Recent insider trading involved Fairmount Funds Management LLC, Director, that happened on Oct 23 ’25 when 0.45 million shares were purchased.
